Regulators in Oregon recently announced that they have approved a licensed testing lab for psilocybin, the first of its kind in the country. The Oregon Health Authority revealed that the license would be awarded to Rose City Labs.
In a press release, Angie Allbee of Oregon Psilocybin Services stated that lab testing ensured correct labeling of the drug’s potency as well as the safety of products. The announcement comes after the Oregon Health Authority granted permission to licensed practitioners to give psilocybin to adults at certain facilities.
Officials were responsible for issuance of licenses to manufacture, test and administer psilocybin by the start of this year as stipulated in the measure approved by voters last year. Thus far, the state’s health authority has approved 60 worker permits.
In a statement, the health authority announced that psilocybin administration sessions could only occur in licensed locations that offered products tested by licensed labs and made by licensed manufacturers. The authority further noted that licensed centers could contract or employ licensed, trained facilitators to support integration and administration sessions with patients.
It should be noted that implementing the psilocybin measure in the state hasn’t been a smooth ride. For instance, local access is still an issue as more than 100 cities in Oregon have passed two-year bans that prevent psilocybin centers from being set up in their regions. Additionally, the Synthesis Institute recently filed for bankruptcy. The institute is a Netherlands-based organization that invested in the creation of training programs on how to administer the drug at treatment centers for psychedelic practitioners.
Despite this, the state’s Psilocybin Advisory Board has continued promoting studies into the potential of psilocybin in treating a range of mental health conditions. In 2021, members presented a report looking into this while the board approved a team of researchers to develop an extensive review of the culture, science and history of the psychedelic.
The state’s decision to legalize saw other states jump on the bandwagon. For example, voters in Colorado approved a ballot resolution to offer controlled access to psilocybin and legalize certain psychedelics. Last week, senators in Colorado passed a measure to establish a regulatory framework for psychedelics under the resolution.
In Hawaii, the Senate passed a measure to establish an advisory council to explore possible regulations to offer access to federal breakthrough treatments such as MDMA and psilocybin. In DC, a legislation promoting studies into psilocybin and establishing a program that offers access to psilocybin for mental health conditions has been forwarded to the governor after approval in the Senate.
These successes in enacting psychedelic policy reform send positive signals to drug-development companies such as Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) and suggest that the legal environment in which they operate could improve soon.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
